基于基因突变的原发性肝癌精准治疗的挑战

周华邦; 胡和平

doi:10.3969/j.issn.1001-5256.2017.07.001

基于基因突变的原发性肝癌精准治疗的挑战

DOI: 10.3969/j.issn.1001-5256.2017.07.001

第二军医大学东方肝胆外科医院肝胆内科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2519
- HTML全文浏览量: 37
- PDF下载量: 533
- 被引次数: 0
出版历程
- 收稿日期: 2017-06-19
- 出版日期: 2017-07-20

Challenges in precise treatment for primary liver cancer based on gene mutation

Department of Hepatobiliary Diseases, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University

摘要

摘要: 基因突变是原发性肝癌发病的分子基础,基于突变基因的精准治疗是未来治疗肝癌最重要的方向。从肝癌基因突变的复杂性、突变基因检测水平以及临床试验局限性等方面介绍了当前肝癌精准治疗的现状、开展肝癌精准治疗的复杂性以及未来的发展前景与方向。指出尽管基于基因突变的肝癌精准治疗当前面临众多的挑战,但精准治疗未来仍是值得期待的。
- 肝肿瘤 /
- 基因 /
- 突变 /
- 治疗 /
- 述评
Abstract: Gene mutation is the molecular basis of the pathogenesis of primary liver cancer, and precise treatment based on gene mutation is an important direction for the treatment of liver cancer in future.This article introduces the current status, complexity, and prospects and future directions of precise treatment for liver cancer from the aspects of complex gene mutations in liver cancer, level of mutation detection, and limitations of clinical trials.It is pointed out that there are many challenges in precise treatment for liver cancer, but precise treatment still has a promising future.
- liver neoplasms /
- genes /
- mutation /
- treatment /
- editorial

HTML全文

参考文献(10)

[1]SUBBIAH V, KURZROCK R.Debunking the delusion that precision oncology is an illusion[J].Oncologist, 2017.[Epub ahead of print].

[2]BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) :a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet, 2017, 389 (10064) :56-66.

[3]IKEDA K, KUDO M, KAWAZOE S, et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J].J Gastroenterol, 2017, 52 (4) :512-519.

[4]LEE JS.The mutational landscape of hepatocellular carcinoma[J].Clin Mol Hepatol, 2015, 21 (3) :220-229.

[5]ZOU S, LI J, ZHOU H, et al.Mutational landscape of intrahepatic cholangiocarcinoma[J].Nat Commun, 2014, 5:5696.

[6] MERIC-BERNSTAM F, BRUSCO L, SHAW K, et al.Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials[J].J Clin Oncol, 2015, 33 (25) :2753-2762.

[7]PRASAD V.Perspective:the precision-oncology illusion[J].Nature, 2016, 537 (7619) :s63.

[8]ABRAHAMS E, ECK SL.Molecular medicine:precision oncology is not an illusion[J].Nature, 2016, 539 (7629) :357.

[9]WHELER JJ, JANKU F, NAING A, et al.Cancer therapy directed by comprehensive genomic profiling:a single center study[J].Cancer Res, 2016, 76 (13) :3690-3701.

[10]SCHWAEDERLE M, PARKER BA, SCHWAB RB, et al.Precision oncology:the UC San Diego Moores Cancer Center PREDICTexperience[J].Mol Cancer Ther, 2016, 15 (4) :743-752.

施引文献

资源附件(0)

访问统计